Do Corporate Alliances Affect Biotechs' Market Performance?
Is there a positive correlation between the number of corporate alliances biotechs have signed and their success at maintaining, or growing, their market valuations since their IPOs? To find out, we took the forty largest biotech IPOs completed in 1996 and 1997 and plotted their recent market valuations and percentage gain or loss over their IPO valuations against the number of significant corporate outlicensings they had signed since IPO.
You may also be interested in...
Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.
The EU’s Medical Device Regulation applies in just over a month’s time and the IVD Regulation in just over a year. But the standards underpinning them are way behind. Will they get the green light at last
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.